Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice

Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice

AbstractRandomized controlled trials (RCTs) are typically conducted in highly selected patient populations to ideally demonstrate unconfounded clinical efficacy of a drug. In the real world, there may be confounding factors, such as comorbidities or less frequent monitoring. It has therefore become...

Full description

Bibliographic Details
Main Authors: Manoela Manova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Margit Hemetsberger, Arkadi Sharkov, Boryana Zidarova, Dimitrina Apostolova, Maria Vasileva, Silvia Terezova, Mila Vlaskovska, Alexandra Savova
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Biotechnology & Biotechnological Equipment
Subjects:
Ribociclib
breast cancer
Bulgaria
real-world data
outcomes
Online Access:https://www.tandfonline.com/doi/10.1080/13102818.2023.2268753

Internet

https://www.tandfonline.com/doi/10.1080/13102818.2023.2268753

Similar Items